The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity

被引:1
|
作者
Peters, Godefridus J. [1 ,2 ]
Kathmann, Ietje [1 ]
Giovannetti, Elisa [1 ,3 ]
Smid, Kees [1 ]
Assaraf, Yehuda G. [4 ]
Jansen, Gerrit [5 ]
机构
[1] Vrije Univ Amsterdam, Amsterdam Univ, Canc Ctr Amsterdam, Dept Med Oncol,Med Ctr, Amsterdam, Netherlands
[2] Med Univ Gdansk, Dept Biochem, Gdansk, Poland
[3] Fdn Pisana Sci, Canc Pharmacol Lab, Pisa, Italy
[4] Technion Israel Inst Technol, Fac Biol, Fred Wyszkowski Canc Res Lab, Haifa, Israel
[5] Vrije Univ Amsterdam, Amsterdam Univ, Amsterdam Rheumatol & Immunol Ctr, Med Ctr, Amsterdam, Netherlands
关键词
leucovorin stereo-isomers; l-leucovorin; thymidylate synthase; 5-fluorouracil; antifolates; pemetrexed; THYMIDYLATE SYNTHASE INHIBITORS; METASTATIC COLORECTAL-CANCER; COUPLED FOLATE TRANSPORTER; CARRIER-MEDIATED TRANSPORT; TUMOR-CELL LINES; 1ST-LINE TREATMENT; FOLINIC ACID; PHASE-III; FOLYLPOLYGLUTAMATE SYNTHETASE; RHEUMATOID-ARTHRITIS;
D O I
10.3389/fphar.2024.1450418
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background L-Leucovorin (l-LV; 5-formyltetrahydrofolate, folinic acid) is a precursor for 5,10-methylenetetrahydrofolate (5,10-CH2-THF), which is important for the potentiation of the antitumor activity of 5-fluorouracil (5FU). LV is also used to rescue antifolate toxicity. LV is commonly administered as a racemic mixture of its l-LV and d-LV stereoisomers. We compared dl-LV with l-LV and investigated whether d-LV would interfere with the activity of l-LV.Methods Using radioactive substrates, we characterized the transport properties of l-LV and d-LV, and compared the efficacy of l-LV with d-LV to potentiate 5FU-mediated thymidylate synthase (TS) inhibition. Using proliferation assays, we investigated their potential to protect cancer cells from cytotoxicity of the antifolates methotrexate, pemetrexed (Alimta), raltitrexed (Tomudex) and pralatrexate (Folotyn).Results l-LV displayed an 8-fold and 3.5-fold higher substrate affinity than d-LV for the reduced folate carrier (RFC/SLC19A1) and proton coupled folate transporter (PCFT/SLC46A1), respectively. In selected colon cancer cell lines, the greatest enhanced efficacy of 5FU was observed for l-LV (2-fold) followed by the racemic mixture, whereas d-LV was ineffective. The cytotoxicity of antifolates in lymphoma and various solid tumor cell lines could be protected very efficiently by l-LV but not by d-LV. This protective effect of l-LV was dependent on cellular RFC expression as corroborated in RFC/PCFT-knockout and RFC/PCFT-transfected cells. Assessment of TS activity in situ showed that TS inhibition by 5FU could be enhanced by l-LV and dl-LV and only partially by d-LV. However, protection from inhibition by various antifolates was solely achieved by l-LV and dl-LV.Conclusion In general l-LV acts similar to the dl-LV formulations, however disparate effects were observed when d-LV and l-LV were used in combination, conceivably by d-LV affecting (anti)folate transport and intracellular metabolism.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] BIOCHEMICAL MODULATION OF COMBINED RADIATION AND 5-FLUOROURACIL TREATMENT OF MURINE TUMORS BY D,L-LEUCOVORIN
    KOVACS, CJ
    DAINER, PM
    EVANS, MJ
    NYCE, J
    ANTICANCER RESEARCH, 1991, 11 (02) : 905 - 909
  • [2] Acute disseminated myelitis associated with 5-fluorouracil and l-leucovorin treatment
    Yokote, H
    Shintani, S
    Shiigai, T
    EUROPEAN NEUROLOGY, 2005, 54 (04) : 214 - 216
  • [3] Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer
    Romero, AO
    Perez, JE
    Cuevas, MA
    Lacava, JA
    Sabatini, CL
    Dominguez, ME
    Rodriguez, R
    Barbieri, MR
    Ortiz, EH
    Salvadori, MA
    Acuna, LAR
    Acuna, JMR
    Langhi, MJ
    Amato, S
    Machiavelli, MR
    Leone, BA
    Vallejo, CT
    Lorusso, V
    DeLena, M
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (01): : 94 - 98
  • [4] LEUCOVORIN AS A CLINICAL POTENTIATOR OF 5-FLUOROURACIL TOXICITY AND ANTICANCER EFFICACY
    BRUCKNER, HW
    SPIGELMAN, M
    MOUNT SINAI JOURNAL OF MEDICINE, 1988, 55 (05): : 390 - 394
  • [5] BASIS FOR THERAPEUTIC SELECTIVITY OF 5-FLUOROURACIL (FURA) BY L-LEUCOVORIN (DL-CP)
    RUSTUM, YM
    PINEDO, HM
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 132 - 132
  • [6] BIOCHEMICAL MODULATION OF 5-FLUOROURACIL BY LEUCOVORIN
    BORNER, M
    BRUNNER, K
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1991, 121 (33) : 1149 - 1156
  • [7] Treatment of advanced colorectal adenocarcinoma with weekly high-dose l-leucovorin and 5-fluorouracil
    Nozue, M
    Isaka, N
    Maruyama, T
    Kawamoto, T
    Seino, K
    Tanagichi, H
    Fukao, K
    ONCOLOGY REPORTS, 2002, 9 (01) : 93 - 96
  • [8] CHEMOENZYMATIC SYNTHESIS OF OPTICALLY PURE L-LEUCOVORIN, AN AUGMENTOR OF 5-FLUOROURACIL CYTOTOXICITY AGAINST CANCER
    UWAJIMA, T
    OSHIRO, T
    EGUCHI, T
    KUGE, Y
    HORIGUCHI, A
    IGARASHI, A
    MOCHIDA, K
    IWAKURA, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 171 (02) : 684 - 689
  • [9] Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G).
    Yamaguchi, Kensei
    Nakajima, Takako Eguchi
    Boku, Narikazu
    Hyodo, Ichinosuke
    Mizusawa, Junki
    Hara, Hiroki
    Nishina, Tomohiro
    Sakamoto, Takeshi
    Shitara, Kohei
    Shinozaki, Katsunori
    Katayama, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [10] Salvage chemotherapy in metastatic breast cancer: An experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin
    Colozza, M
    Gori, S
    Mosconi, AM
    Anastasi, P
    Basurto, C
    Ludovini, V
    DeAngelis, V
    Giansanti, M
    Tonato, M
    BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (03) : 277 - 282